After resolving a delay in its biliary cholangitis (PBC) program, CymaBay Therapeutics (NASDAQ:CBAY) is activating clinical sites in North America and Europe, and recruiting patients in its global RESPONSE registration...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
PharmaJet names Paul LaBarre as VP global business development
PharmaJet named Paul LaBarre as VP of global business development to lead business development and commercialization strategies, replacing Melissa Malhame, who transitioned to a strategic advisory role for the company...
Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study
Clearside Biomedical (NASDAQ:CLSD) reported positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX, an axitinib injectable suspension, which is administered by suprachoroidal...
Accelmed Partners bolsters senior HealthTech executive team
Eric Tansky, former managing director in Oppenheimer’s medical technology practice, has joined Accelmed Partners, a private equity firm in HealthTech, as a general partner, and Stephen Rubin, former co-head of...
HCW starts Metacrine at buy; PT $15
H.C. Wainwright launched coverage of Metacrine (NASDAQ:MTCR) with a “buy” rating and $15 price target. The stock closed at $4.14 on June 11. Metacrine is a clinical-stage biopharmaceutical company focused on discovering...
Cantor ups RAPT Therapeutics PT to $71 from $51
Cantor Fitzgerald raised its price target for RAPT Therapeutics (NASDAQ:RAPT) to $71 from $51, citing an increased probability of success for RPT193 in atopic dermatitis to 50% from 25% previously, and taking up peak...
Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics
Lucid Psycheceuticals inked a world-wide license agreement with Toronto’s University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications...
Cantor starts CareCloud at OW: PT $15
Cantor Fitzgerald launched coverage of CareCloud (NASDAQ:MTBC) with an “overweight” rating and $15 price target. The stock closed at $8.54 on June 10. CareCloud, formerly known as MTBC Inc., provides a broad range of...
iBio adds veteran biopharmaceutical executive Evert Schimmelpennink to board
iBio (NYSEA:IBIO) appointed Evert (Eef) Schimmelpennink to its board of directors, effective immediately. In an executive leadership career spanning more than 20 years, Mr. Schimmelpennink has expertise across corporate...
AGP starts Myomo at buy; PT $36.50
Alliance Global Partners initiated coverage of Myomo (NYSEA:MYO) with a “buy” rating and price target of $36.50. The stock closed at $10.19 on June 9. “Myomo, in our view, represents one of the most compelling stories...
Hepion Pharmaceuticals to be added to the Russell Microcap Index
Hepion Pharmaceuticals (NASDAQ:HEPA) is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28. Membership in the...
Veterinary healthcare company evaluating IntelGenx VetaFilm platform
IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a materials transfer agreement with an undisclosed global veterinary healthcare company to evaluate IntelGenx’s proprietary VetaFilm platform in cats. Based on a successful...
HCW starts UNITY Biotechnology at buy; PT $12
H.C. Wainwright launched coverage of UNITY Biotechnology (NASDAQ:UBX) with a “buy” rating and $12 price target. The stock closed at $4.56 on June 4. UNITY is focusing on therapeutics addressing diseases of aging, while...
Just a few of the companies we’ve highlighted along the way
